0

Orthostatic Hypotension Drugs Market by Product and Geography - Forecast and Analysis 2022-2026

  • Published: Mar 2022
  • Pages: 142
  • SKU: IRTNTR72405
Technavio

Purchase this report now and if we publish a new version within 90 days, we will send you a free copy.

Safe and Secure SSL Encrypted
  • 2500.00
  • USD

The orthostatic hypotension drugs market share is expected to increase by USD 571.76 million from 2021 to 2026, and the market’s growth momentum will accelerate at a CAGR of 9.06%.

This orthostatic hypotension drugs market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers orthostatic hypotension drugs market segmentations by product (midodrine, northera (droxidopa), fludrocortisone, and other drugs) and geography (North America, Europe, Asia, and Rest of World (ROW)). The orthostatic hypotension drugs market report also offers information on several market vendors, including Alchemy Laboratories Pvt Ltd., Alembic Pharmaceuticals Ltd., Amneal Pharmaceuticals Inc., Apotex Inc., Avadel Pharmaceuticals plc, Baxter International Inc., Brancaster Pharma Ltd., Cadila Healthcare Ltd., Cerecor Inc., Enaltec Labs Pvt. Ltd., Endo International Plc, H. Lundbeck AS, Hikma Pharmaceuticals Plc, J B Chemicals and Pharmaceuticals Ltd., Manus Aktteva Biopharma LLP, Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Theravance Biopharma Inc., and Viatris Inc. among others.

What will the Orthostatic Hypotension Drugs Market Size be During the Forecast Period?

Download the Free Report Sample to Unlock the Orthostatic Hypotension Drugs Market Size for the Forecast Period and Other Important Statistics

 

Orthostatic Hypotension Drugs Market: Key Drivers, Trends, and Challenges

The increasing prevalence of OH in the geriatric population is notably driving the orthostatic hypotension drugs market growth, although factors such as the low diagnosis rate of oh may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the orthostatic hypotension drugs industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.

Key Orthostatic Hypotension Drugs Market Driver

The increasing prevalence of OH in the geriatric population is one of the key drivers supporting the orthostatic hypotension drugs market growth. OH is a common condition in geriatric patients and is associated with significant morbidity and mortality. The geriatric population is prone to chronic diseases that require polypharmacy for treatment, one of the major risk factors of OH. Moreover, the geriatric population often requires hospital admissions due to illness or injuries. The bedrest confinement during hospitalization may lead to physiological deconditioning, functional decline, and OH. In addition, barosensory vessel wall stiffness increases with age while cardio-vagal autonomic control effectiveness decreases, which raises the risk of it. These factors are expected to drive the demand for OH treatment, which will contribute to the growth of the global OH drugs market during the forecast period.

Key Orthostatic Hypotension Drugs Market Trend

Research and Development of new drugs for OH treatment is one of the key orthostatic hypotension drugs market trends that is contributing to the market growth. There is a high unmet need for drugs in the OH drugs market due to a lack of approval with substantial clinical efficiency and high safety profile. Hence, there is an increasing focus on R and D of novel drugs to cater to the unmet need in OH pharmacological therapy. For instance, Lundbeck LLC conducted Phase 5 clinical trials (post-marketing study) in the US to assess the sustained effects of droxidopa therapy in patients with nOH. The study was completed in December 2020 and Theravance Biopharma Inc. announced the positive topline four-week data from the Phase 2 clinical trial of ampreloxetine for the treatment of symptomatic nOH. These initiatives are expected to boost the market growth during the forecast period.

Key Orthostatic Hypotension Drugs Market Challenge

The low diagnosis rate of OH is one of the factors hindering the orthostatic hypotension drugs market growth. Though OH is common in the geriatric population and is associated with substantial morbidity and variable prognosis, its diagnosis rate is low. This is because OH remains asymptomatic in most cases. In general, patients do not initiate a discussion about their nOH symptoms with their healthcare providers unless the symptoms are severe. Hence, it is difficult to manage OH in patients with several complex medical issues such as PD that are challenging to manage. Patients often hide or minimize their nOH symptoms as they view symptoms as a sign of weakness or because they are embarrassed. Furthermore, most patients are unaware that nOH can be associated with PD. Hence, the lack of diagnosis of nOH results in a delay in the treatment of OH, which may restrict the market uptake of OH drugs.

This orthostatic hypotension drugs market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.

Parent Market Analysis

Technavio categorizes the global orthostatic hypotension (OH) drugs market as a part of the pharmaceutical market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the orthostatic hypotension drugs market during the forecast period.

Who are the Major Orthostatic Hypotension Drugs Market Vendors?

The report analyzes the market’s competitive landscape and offers information on several market vendors, including:

 

  • Alchemy Laboratories Pvt Ltd.
  • Alembic Pharmaceuticals Ltd.
  • Amneal Pharmaceuticals Inc.
  • Apotex Inc.
  • Avadel Pharmaceuticals plc
  • Baxter International Inc.
  • Brancaster Pharma Ltd.
  • Cadila Healthcare Ltd.
  • Cerecor Inc.
  • Enaltec Labs Pvt. Ltd.
  • Endo International Plc
  • H. Lundbeck AS
  • Hikma Pharmaceuticals Plc
  • J B Chemicals and Pharmaceuticals Ltd.
  • Manus Aktteva Biopharma LLP
  • Novartis AG
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Theravance Biopharma Inc.
  • Viatris Inc.

 

This statistical study of the orthostatic hypotension drugs market encompasses successful business strategies deployed by the key vendors. The orthostatic hypotension drugs market is fragmented and the vendors are deploying growth strategies such as expanding their product portfolios by investing in R and D to compete in the market.

Product Insights and News

  • Amneal Pharmaceuticals Inc. - Under the specialty segment, the company is involved in the development, promotion, sale, and distribution of proprietary branded pharmaceutical products, with a focus on products addressing central nervous system disorders, including migraine and Parkinson's disease. 
  • Amneal Pharmaceuticals Inc. - The company offers orthostatic hypotension drugs that have the strength of 0.1 mg and are available in dosage form of tablets, under the brand name of Fludrocortisone Acetate USP. 

To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The orthostatic hypotension drugs market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.

Orthostatic Hypotension Drugs Market Value Chain Analysis

Our report provides extensive information on the value chain analysis for the orthostatic hypotension drugs market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.

Which are the Key Regions for Orthostatic Hypotension Drugs Market?

For more insights on the market share of various regions Request for a FREE sample now!

42% of the market’s growth will originate from North America during the forecast period. US and Canada are the key markets for the orthostatic hypotension drugs market in North America. Market growth in this region will be faster than the growth of the market in ROW.

The high per capita pharmaceutical expenditure will facilitate the orthostatic hypotension drugs market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

COVID Impact and Recovery Analysis

The COVID-19 pandemic had a positive impact on the OH drugs market in North America in 2020. Moreover, North America is projected to account for the major share of the global OH drugs market during the forecast period due to its well-established healthcare infrastructure and presence of key players in the market.

What are the Revenue-generating Product Segments in the Orthostatic Hypotension Drugs Market?

To gain further insights on the market contribution of various segments Request for a FREE sample

The orthostatic hypotension drugs market share growth by the midodrine segment will be significant during the forecast period. Midodrine is a pro-drug that rapidly converts to its active metabolite desglymidodrine, which is a selective alpha1-adrenergic agonist that increases blood pressure by inducing vasoconstriction. It is the first drug that was approved in the US for the treatment of OH in 1996, under the FDA accelerated approval regulation for medications for the treatment of serious or life-threatening diseases. It is also approved for the treatment of OH in some European countries, such as Germany, France, and the UK. Such increasing approval will drive the segment growth during the forecast period.

This report provides an accurate prediction of the contribution of all the segments to the growth of the orthostatic hypotension drugs market size and actionable market insights on post COVID-19 impact on each segment.

 

Orthostatic Hypotension Drugs Market Scope

Report Coverage

Details

Page number

120

Base year

2021

Forecast period

2022-2026

Growth momentum & CAGR

Accelerate at a CAGR of 9.06%

Market growth 2022-2026

$ 571.76 million

Market structure

Fragmented

YoY growth (%)

6.44

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 42%

Key consumer countries

US, Canada, Germany, UK, and China

Competitive landscape

Leading companies, Competitive strategies, Consumer engagement scope

Key companies profiled

Alchemy Laboratories Pvt Ltd., Alembic Pharmaceuticals Ltd., Amneal Pharmaceuticals Inc., Apotex Inc., Avadel Pharmaceuticals plc, Baxter International Inc., Brancaster Pharma Ltd., Cadila Healthcare Ltd., Cerecor Inc., Enaltec Labs Pvt. Ltd., Endo International Plc, H. Lundbeck AS, Hikma Pharmaceuticals Plc, J B Chemicals and Pharmaceuticals Ltd., Manus Aktteva Biopharma LLP, Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Theravance Biopharma Inc., and Viatris Inc.

Market dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request for a FREE sample

What are the Key Data Covered in this Orthostatic Hypotension Drugs Market Report?

  • CAGR of the market during the forecast period 2022-2026
  • Detailed information on factors that will drive orthostatic hypotension drugs market growth during the next five years
  • Precise estimation of the orthostatic hypotension drugs market size and its contribution to the parent market
  • Accurate predictions on upcoming trends and changes in consumer behavior
  • The growth of the orthostatic hypotension drugs industry across North America, Europe, Asia, and Rest of World (ROW)
  • A thorough analysis of the market’s competitive landscape and detailed information on vendors
  • Comprehensive details of factors that will challenge the growth of orthostatic hypotension drugs market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch

Read More Read Less

1 Executive Summary

  • 1.1 Market overview
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by Product
    • Exhibit 06: Executive Summary – Chart on Incremental Growth
    • Exhibit 07: Executive Summary – Data Table on Incremental Growth
    • Exhibit 08: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Exhibit 09: Parent market
    • Exhibit 10: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
    • Exhibit 11: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
    • Exhibit 12: Market segments
  • 3.3 Market size 2021
    • 3.4 Market outlook: Forecast for 2021-2026
      • Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
      • Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
      • Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
      • Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)

    4 Five Forces Analysis

    • 4.1 Five forces summary
      • Exhibit 17: Five forces analysis - Comparison between 2021 and 2026
    • 4.2 Bargaining power of buyers
      • Exhibit 18: Bargaining power of buyers – Impact of key factors in 2021 and 2026
    • 4.3 Bargaining power of suppliers
      • Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026
    • 4.4 Threat of new entrants
      • Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026
    • 4.5 Threat of substitutes
      • Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026
    • 4.6 Threat of rivalry
      • Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026
    • 4.7 Market condition
      • Exhibit 23: Chart on Market condition - Five forces 2021 and 2026

    5 Market Segmentation by Product

    • 5.1 Market segments
      • Exhibit 24: Chart on Product - Market share 2021-2026 (%)
      • Exhibit 25: Data Table on Product - Market share 2021-2026 (%)
    • 5.2 Comparison by Product
      • Exhibit 26: Chart on Comparison by Product
      • Exhibit 27: Data Table on Comparison by Product
    • 5.3 Midodrine - Market size and forecast 2021-2026
      • Exhibit 28: Chart on Midodrine - Market size and forecast 2021-2026 ($ million)
      • Exhibit 29: Data Table on Midodrine - Market size and forecast 2021-2026 ($ million)
      • Exhibit 30: Chart on Midodrine - Year-over-year growth 2021-2026 (%)
      • Exhibit 31: Data Table on Midodrine - Year-over-year growth 2021-2026 (%)
    • 5.4 Northera (droxidopa) - Market size and forecast 2021-2026
      • Exhibit 32: Chart on Northera (droxidopa) - Market size and forecast 2021-2026 ($ million)
      • Exhibit 33: Data Table on Northera (droxidopa) - Market size and forecast 2021-2026 ($ million)
      • Exhibit 34: Chart on Northera (droxidopa) - Year-over-year growth 2021-2026 (%)
      • Exhibit 35: Data Table on Northera (droxidopa) - Year-over-year growth 2021-2026 (%)
    • 5.5 Fludrocortisone - Market size and forecast 2021-2026
      • Exhibit 36: Chart on Fludrocortisone - Market size and forecast 2021-2026 ($ million)
      • Exhibit 37: Data Table on Fludrocortisone - Market size and forecast 2021-2026 ($ million)
      • Exhibit 38: Chart on Fludrocortisone - Year-over-year growth 2021-2026 (%)
      • Exhibit 39: Data Table on Fludrocortisone - Year-over-year growth 2021-2026 (%)
    • 5.6 Other drugs - Market size and forecast 2021-2026
      • Exhibit 40: Chart on Other drugs - Market size and forecast 2021-2026 ($ million)
      • Exhibit 41: Data Table on Other drugs - Market size and forecast 2021-2026 ($ million)
      • Exhibit 42: Chart on Other drugs - Year-over-year growth 2021-2026 (%)
      • Exhibit 43: Data Table on Other drugs - Year-over-year growth 2021-2026 (%)
    • 5.7 Market opportunity by Product
      • Exhibit 44: Market opportunity by Product ($ million)

    6 Customer Landscape

    • 6.1 Customer landscape overview
      • Exhibit 45: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

    7 Geographic Landscape

    • 7.1 Geographic segmentation
      • Exhibit 46: Chart on Market share by geography 2021-2026 (%)
      • Exhibit 47: Data Table on Market share by geography 2021-2026 (%)
    • 7.2 Geographic comparison
      • Exhibit 48: Chart on Geographic comparison
      • Exhibit 49: Data Table on Geographic comparison
    • 7.3 North America - Market size and forecast 2021-2026
      • Exhibit 50: Chart on North America - Market size and forecast 2021-2026 ($ million)
      • Exhibit 51: Data Table on North America - Market size and forecast 2021-2026 ($ million)
      • Exhibit 52: Chart on North America - Year-over-year growth 2021-2026 (%)
      • Exhibit 53: Data Table on North America - Year-over-year growth 2021-2026 (%)
    • 7.4 Europe - Market size and forecast 2021-2026
      • Exhibit 54: Chart on Europe - Market size and forecast 2021-2026 ($ million)
      • Exhibit 55: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
      • Exhibit 56: Chart on Europe - Year-over-year growth 2021-2026 (%)
      • Exhibit 57: Data Table on Europe - Year-over-year growth 2021-2026 (%)
    • 7.5 Asia - Market size and forecast 2021-2026
      • Exhibit 58: Chart on Asia - Market size and forecast 2021-2026 ($ million)
      • Exhibit 59: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
      • Exhibit 60: Chart on Asia - Year-over-year growth 2021-2026 (%)
      • Exhibit 61: Data Table on Asia - Year-over-year growth 2021-2026 (%)
    • 7.6 Rest of World (ROW) - Market size and forecast 2021-2026
      • Exhibit 62: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
      • Exhibit 63: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
      • Exhibit 64: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
      • Exhibit 65: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
    • 7.7 US - Market size and forecast 2021-2026
      • Exhibit 66: Chart on US - Market size and forecast 2021-2026 ($ million)
      • Exhibit 67: Data Table on US - Market size and forecast 2021-2026 ($ million)
      • Exhibit 68: Chart on US - Year-over-year growth 2021-2026 (%)
      • Exhibit 69: Data Table on US - Year-over-year growth 2021-2026 (%)
    • 7.8 Canada - Market size and forecast 2021-2026
      • Exhibit 70: Chart on Canada - Market size and forecast 2021-2026 ($ million)
      • Exhibit 71: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
      • Exhibit 72: Chart on Canada - Year-over-year growth 2021-2026 (%)
      • Exhibit 73: Data Table on Canada - Year-over-year growth 2021-2026 (%)
    • 7.9 Germany - Market size and forecast 2021-2026
      • Exhibit 74: Chart on Germany - Market size and forecast 2021-2026 ($ million)
      • Exhibit 75: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
      • Exhibit 76: Chart on Germany - Year-over-year growth 2021-2026 (%)
      • Exhibit 77: Data Table on Germany - Year-over-year growth 2021-2026 (%)
    • 7.10 China - Market size and forecast 2021-2026
      • Exhibit 78: Chart on China - Market size and forecast 2021-2026 ($ million)
      • Exhibit 79: Data Table on China - Market size and forecast 2021-2026 ($ million)
      • Exhibit 80: Chart on China - Year-over-year growth 2021-2026 (%)
      • Exhibit 81: Data Table on China - Year-over-year growth 2021-2026 (%)
    • 7.11 UK - Market size and forecast 2021-2026
      • Exhibit 82: Chart on UK - Market size and forecast 2021-2026 ($ million)
      • Exhibit 83: Data Table on UK - Market size and forecast 2021-2026 ($ million)
      • Exhibit 84: Chart on UK - Year-over-year growth 2021-2026 (%)
      • Exhibit 85: Data Table on UK - Year-over-year growth 2021-2026 (%)
    • 7.12 Market opportunity by geography
      • Exhibit 86: Market opportunity by geography ($ million)

    8 Drivers, Challenges, and Trends

    • 8.1 Market drivers
      • 8.2 Market challenges
        • 8.3 Impact of drivers and challenges
          • Exhibit 87: Impact of drivers and challenges in 2021 and 2026
        • 8.4 Market trends

          9 Vendor Landscape

          • 9.1 Overview
            • 9.2 Vendor landscape
              • Exhibit 88: Overview on Criticality of inputs and Factors of differentiation
            • 9.3 Landscape disruption
              • Exhibit 89: Overview on factors of disruption
            • 9.4 Industry risks
              • Exhibit 90: Impact of key risks on business

            10 Vendor Analysis

            • 10.1 Vendors covered
              • Exhibit 91: Vendors covered
            • 10.2 Market positioning of vendors
              • Exhibit 92: Matrix on vendor position and classification
            • 10.3 Amneal Pharmaceuticals Inc.
              • Exhibit 93: Amneal Pharmaceuticals Inc. - Overview
              • Exhibit 94: Amneal Pharmaceuticals Inc. - Business segments
              • Exhibit 95: Amneal Pharmaceuticals Inc. - Key offerings
              • Exhibit 96: Amneal Pharmaceuticals Inc. - Segment focus
            • 10.4 Apotex Inc.
              • Exhibit 97: Apotex Inc. - Overview
              • Exhibit 98: Apotex Inc. - Product / Service
              • Exhibit 99: Apotex Inc. - Key offerings
            • 10.5 Avadel Pharmaceuticals plc
              • Exhibit 100: Avadel Pharmaceuticals plc - Overview
              • Exhibit 101: Avadel Pharmaceuticals plc - Business segments
              • Exhibit 102: Avadel Pharmaceuticals plc - Key news
              • Exhibit 103: Avadel Pharmaceuticals plc - Key offerings
              • Exhibit 104: Avadel Pharmaceuticals plc - Segment focus
            • 10.6 Baxter International Inc.
              • Exhibit 105: Baxter International Inc. - Overview
              • Exhibit 106: Baxter International Inc. - Business segments
              • Exhibit 107: Baxter International Inc. - Key offerings
              • Exhibit 108: Baxter International Inc. - Segment focus
            • 10.7 Endo International Plc
              • Exhibit 109: Endo International Plc - Overview
              • Exhibit 110: Endo International Plc - Business segments
              • Exhibit 111: Endo International Plc - Key news
              • Exhibit 112: Endo International Plc - Key offerings
              • Exhibit 113: Endo International Plc - Segment focus
            • 10.8 H. Lundbeck AS
              • Exhibit 114: H. Lundbeck AS - Overview
              • Exhibit 115: H. Lundbeck AS - Business segments
              • Exhibit 116: H. Lundbeck AS - Key offerings
              • Exhibit 117: H. Lundbeck AS - Segment focus
            • 10.9 Novartis AG
              • Exhibit 118: Novartis AG - Overview
              • Exhibit 119: Novartis AG - Business segments
              • Exhibit 120: Novartis AG - Key offerings
              • Exhibit 121: Novartis AG - Segment focus
            • 10.10 Pfizer Inc.
              • Exhibit 122: Pfizer Inc. - Overview
              • Exhibit 123: Pfizer Inc. - Business segments
              • Exhibit 124: Pfizer Inc. - Key news
              • Exhibit 125: Pfizer Inc. - Key offerings
              • Exhibit 126: Pfizer Inc. - Segment focus
            • 10.11 Teva Pharmaceutical Industries Ltd.
              • Exhibit 127: Teva Pharmaceutical Industries Ltd. - Overview
              • Exhibit 128: Teva Pharmaceutical Industries Ltd. - Business segments
              • Exhibit 129: Teva Pharmaceutical Industries Ltd. - Key news
              • Exhibit 130: Teva Pharmaceutical Industries Ltd. - Key offerings
              • Exhibit 131: Teva Pharmaceutical Industries Ltd. - Segment focus
            • 10.12 Viatris Inc.
              • Exhibit 132: Viatris Inc. - Overview
              • Exhibit 133: Viatris Inc. - Business segments
              • Exhibit 134: Viatris Inc. - Key offerings
              • Exhibit 135: Viatris Inc. - Segment focus

            11 Appendix

            • 11.1 Scope of the report
              • 11.2 Inclusions and exclusions checklist
                • Exhibit 136: Inclusions checklist
                • Exhibit 137: Exclusions checklist
              • 11.3 Currency conversion rates for US$
                • Exhibit 138: Currency conversion rates for US$
              • 11.4 Research methodology
                • Exhibit 139: Research methodology
                • Exhibit 140: Validation techniques employed for market sizing
                • Exhibit 141: Information sources
              • 11.5 List of abbreviations
                • Exhibit 142: List of abbreviations

              Research Framework

              Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

              TechnavioINFORMATION SOURCES

              Primary sources

              • Manufacturers and suppliers
              • Channel partners
              • Industry experts
              • Strategic decision makers

              Secondary sources

              • Industry journals and periodicals
              • Government data
              • Financial reports of key industry players
              • Historical data
              • Press releases
              Technavio

              TechnavioDATA ANALYSIS

              Data Synthesis

              • Collation of data
              • Estimation of key figures
              • Analysis of derived insights

              Data Validation

              • Triangulation with data models
              • Reference against proprietary databases
              • Corroboration with industry experts
              Technavio

              TechnavioREPORT WRITING

              Qualitative

              • Market drivers
              • Market challenges
              • Market trends
              • Five forces analysis

              Quantitative

              • Market size and forecast
              • Market segmentation
              • Geographical insights
              • Competitive landscape
              Interested in this report?
              Get your FREE sample now!
              The orthostatic hypotension drugs market growth will increase by $571.76 million during 2022-2026.
              The orthostatic hypotension drugs market is expected to grow at a CAGR of 9.06% during 2022-2026.
              Technavio has segmented the orthostatic hypotension drugs market by product (Midodrine, Northera (droxidopa), Fludrocortisone, and Other drugs) and geographic (North America, Europe, Asia, and Rest of World (ROW)).
              Alchemy Laboratories Pvt Ltd., Alembic Pharmaceuticals Ltd., Amneal Pharmaceuticals Inc., Apotex Inc., Avadel Pharmaceuticals plc, Baxter International Inc., Brancaster Pharma Ltd., Cadila Healthcare Ltd., Cerecor Inc., Enaltec Labs Pvt. Ltd., Endo International Plc, H. Lundbeck AS, Hikma Pharmaceuticals Plc, J B Chemicals and Pharmaceuticals Ltd., Manus Aktteva Biopharma LLP, Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Theravance Biopharma Inc., Viatris Inc. are a few of the key vendors in the orthostatic hypotension drugs market.
              North America will register the highest growth rate of 42.34% among the other regions. Therefore, the orthostatic hypotension drugs market in North America is expected to garner significant business opportunities for the vendors during the forecast period.
              The key factors driving the orthostatic hypotension drugs market growth are:
              • Increasing prevalence of OH in geriatric population
              • Research and Development of new drugs for OH treatment
              The orthostatic hypotension drugs market vendors should focus on grabbing business opportunities from the midodrine segment as it accounted for the largest market share in the base year.
              Safe and Secure SSL Encrypted
              Technavio

              Single User:

              2500 USD

              Technavio Get the report (PDF) sent to your email within minutes.

              Subscribe & Save

              Get lifetime access to our
              Technavio Insights

              Want to customize this report?

              This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time.

              We offer $1000 worth of FREE customization at the time of purchase
              Technavio
              Enquire Before Buying
              1. Home
              2. Health Care
              3. Published Report
              17,000 reports available | Plans starting from just 5,000 USD | Get FREE trial>>